Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

High Risk Cytogenetic Abnormalities Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients Received Autologous Hematopoietic Cell Transplantation

Blood (2024) 144 (Supplement 1): 6925.

https://doi.org/10.1182/blood-2024-205155

Published: 2024

Journal Articles

In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study

Rong Fu, Hong Yu, Aijun Liu, Rui Hou, Zunmin Zhu, Junling Zhuang, Li Bao, Zhenling Li, Lihong Liu, Luoming Hua, Yanping Ma, Da Gao, ARong Jin, Xiaohui Suo, Wei Yang, Yuansong Bai, Deqiang Zheng, Wenming Chen

Blood (2024) 144 (Supplement 1): 7846.

https://doi.org/10.1182/blood-2024-209471

Published: 2024

Journal Articles

Spruce-TN CLL/SLL (cwCLL-002 study): An Ongoing Study of MRD-Guided Sonrotoclax Plus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

Shuhua Yi, Tingyu Wang, Fei Li, Jingdong Zhang, Xingli Zou, Yanping Ma, Lugui Qiu

Blood (2024) 144 (Supplement 1): 1875.1.

https://doi.org/10.1182/blood-2024-201175

Published: 2024

Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Miao Chen, Hong Yu, Aijun Liu, Wei Wang, Xiaoqi Qin, Ziping Li, Yanping Ma, Wenming Chen, Rong Fu, Junling Zhuang

Blood (2024) 144 (Supplement 1): 7038.

https://doi.org/10.1182/blood-2024-210284

Published: 2024

Journal Articles

Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China

Blood (2024) 144 (Supplement 1): 1767.

https://doi.org/10.1182/blood-2024-206453

Published: 2024

Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: Preliminary Analysis from a Phase 2, Prospective, Multicenter Study

Blood (2024) 144 (Supplement 1): 1978.

https://doi.org/10.1182/blood-2024-201978

Published: 2024

Journal Articles

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Blood (2024) 144 (Supplement 1): 4529.

https://doi.org/10.1182/blood-2024-203533

Published: 2024

Journal Articles

Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China

Blood (2024) 144 (Supplement 1): 4528.

https://doi.org/10.1182/blood-2024-205232

Published: 2024

Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Blood (2023) 142 (Supplement 1): 4754.

https://doi.org/10.1182/blood-2023-180736

Published: 2023

Journal Articles

The Efficacy and Safety of Zanubrutinib, Dexamethasone and or Not Cyclophosphamide Regimen in Symptomatic Waldenstrom Macroglobulinnemia

Aijun Liu, Jin Lu, Yanping Ma, Da Gao, Luoming Hua, Yuechen Zhang, Chuanying Geng, Ying Tian, Yun Leng, Wenming Chen

Blood (2023) 142 (Supplement 1): 6699.

https://doi.org/10.1182/blood-2023-189130

Published: 2023

Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Miao Chen, Rong Fu, Wenming Chen, Wei Wang, Yanping Ma, Junling Zhuang

Blood (2023) 142 (Supplement 1): 6696.

https://doi.org/10.1182/blood-2023-187828

Published: 2023

Journal Articles

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimen for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Blood (2022) 140 (Supplement 1): 12637–12639.

https://doi.org/10.1182/blood-2022-169057

Published: 2022

Journal Articles

Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Blood (2022) 140 (Supplement 1): 10167–10169.

https://doi.org/10.1182/blood-2022-159361

Published: 2022

Journal Articles

Lenalidomide Versus Thalidomide or Bortezomib As Maintenance Regimens for Non-Transplant Patients with Multiple Myeloma: Multi-Center Real World Experience in China

Zhe Zhuang, Lei Shi, Ying Tian, Dongmei Zou, Ru Feng, Fei Dong, Yanping Ma, Hong Yu, Wei-wei Tian, Shuangjiao Liu, Liangming Ma, Rong Fu, Hongmei Jing, Hui Liu, Wanling Sun, Chen Wenming, Yin Wu, Li Bao, Junling Zhuang

Blood (2021) 138 (Supplement 1): 4728.

https://doi.org/10.1182/blood-2021-149502

Published: 2021

Journal Articles

Trial in Progress: A Perspective Study of Pan-Oral Triplet Regimen Pomalidomide, Ixazomib and Dexamethasone in Relapsed or Refractory Myeloma Patients

Miao Chen, Li Bao, Wenming Chen, Rong Fu, Rong Guo, Hongmei Jing, Hui Liu, Qinhua Liu, Yanping Ma, Xiuli SUN, Wei Wang, Yafei Wang, Xiaojing Yan, Jiang Qian, Junling Zhuang

Blood (2021) 138 (Supplement 1): 4783.

https://doi.org/10.1182/blood-2021-148237

Published: 2021

Journal Articles

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimens for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Blood (2021) 138 (Supplement 1): 4766.

https://doi.org/10.1182/blood-2021-152542

Published: 2021

Journal Articles

Sequential Intravenous to Oral Proteasome Inhibitor Based Regimens for the Treatment of Newly Diagnosed Multiple Myeloma Patients: A Real-World Study

Aijun Liu, Rong Fu, PhD, Zunmin Zhu, Li Bao, MD, Huizheng Bao, Da Gao, MD, Yanping Ma, PhD, Chen Wenming, MD, Hong Yu

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-139064

Published: 2020

Journal Articles

Clinical Study Of DC-CIK (dendritic cells and cytokine-induced killer cells ) Eliminate Minimal Residual Leukemia

Zhuanzhen Zheng, MD, PhD, Zhang Yuna, Zhang Huimin, Qingchi Liu, Yanping Ma, Weihai Wu, Chuanbao MA, Yuhui Pang, Jianying LI

Blood (2013) 122 (21): 1450.

https://doi.org/10.1182/blood.V122.21.1450.1450

Published: 2013

Journal Articles

The Study On The Relationship Between c-Myc and Hif-1 α In u266 Cell Line

Yanping Ma

Blood (2013) 122 (21): 5337.

https://doi.org/10.1182/blood.V122.21.5337.5337

Published: 2013

Journal Articles

Using Auto Dendritic Cells Accompanied with CIK Plus Chemotherapy As Consolidation Treatment for 59 Patients with Acute Leukemia

Zhuanzhen Zheng, MD, PhD, Zhenhua Qiao, MD, Wenliang Chen, MD, Rong Gong, MD, Yalin Wang, MD, Lianrong Xu, MD, PhD, Yanping Ma, MD, PhD, Lihong Hou, MD, PhD, Li Zhang, MD, PhD, Yujin Lu, Bo Jiang, MD, Guoxia Li, Chunxia Dong, MD, PhD

Blood (2011) 118 (21): 4923.

https://doi.org/10.1182/blood.V118.21.4923.4923

Published: 2011

NARROW

High Risk Cytogenetic Abnormalities Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients Received Autologous Hematopoietic Cell Transplantation

In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study

Spruce-TN CLL/SLL (cwCLL-002 study): An Ongoing Study of MRD-Guided Sonrotoclax Plus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: Preliminary Analysis from a Phase 2, Prospective, Multicenter Study

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

The Efficacy and Safety of Zanubrutinib, Dexamethasone and or Not Cyclophosphamide Regimen in Symptomatic Waldenstrom Macroglobulinnemia

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimen for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Lenalidomide Versus Thalidomide or Bortezomib As Maintenance Regimens for Non-Transplant Patients with Multiple Myeloma: Multi-Center Real World Experience in China

Trial in Progress: A Perspective Study of Pan-Oral Triplet Regimen Pomalidomide, Ixazomib and Dexamethasone in Relapsed or Refractory Myeloma Patients

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimens for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Sequential Intravenous to Oral Proteasome Inhibitor Based Regimens for the Treatment of Newly Diagnosed Multiple Myeloma Patients: A Real-World Study

Clinical Study Of DC-CIK (dendritic cells and cytokine-induced killer cells ) Eliminate Minimal Residual Leukemia

The Study On The Relationship Between c-Myc and Hif-1 α In u266 Cell Line

Using Auto Dendritic Cells Accompanied with CIK Plus Chemotherapy As Consolidation Treatment for 59 Patients with Acute Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only